{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:02:16Z","timestamp":1773522136391,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005744","name":"Lastentautien Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["240050"],"award-info":[{"award-number":["240050"]}],"id":[{"id":"10.13039\/501100005744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis\u2013ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with\/without confirmed PSC. Different preparations had shown different efficacy. We compared oral vancomycin solution to capsules in inducing remission in children with atypical colitis, while assessing other potential confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Children using oral vancomycin for at least 3\u2009months to manage atypical colitis were retrospectively identified. Factors associated with colitis remission (Paediatric Ulcerative Colitis Activity Index [PUCAI], faecal calprotectin, colonoscopy and histology) were explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 32\/48 children with elevated PUCAI, 27\/32 achieved PUCAI\u2009&lt;\u00a010 (20\/23 after solution <jats:italic>vs<\/jats:italic>. 7\/9 after capsules, <jats:italic>P\u2009=<\/jats:italic>\u00a0.520). Faecal calprotectin &lt;100\u2009\u03bcg\/g was achieved in 35\/48 (28\/35 after solution <jats:italic>vs<\/jats:italic>. 6\/13 after capsules, <jats:italic>P\u2009=<\/jats:italic>\u00a0.022). Follow\u2010up colonoscopy during treatment (<jats:italic>n\u2009=<\/jats:italic>\u00a025) showed reduced Mayo from median 2 to 0 (<jats:italic>P\u2009&lt;<\/jats:italic>\u00a0.001) after solution <jats:italic>vs<\/jats:italic>. from 2 to 1 (<jats:italic>P\u2009=<\/jats:italic>\u00a0.257) after capsules. Pan\u2010colonic histological remission was seen in 14\/25 (12\/20 after solution <jats:italic>vs<\/jats:italic>. 1\/5 after capsules, <jats:italic>P\u2009=<\/jats:italic>\u00a0.109). In adjusted analysis, use of oral vancomycin solution was a significant predictor for biomarker (adjusted odds ratio 23.1, 95% confidence interval 2.11\u2013253) and pan\u2010colonic histological remission (adjusted odds ratio 900, 95% confidence interval 1.61\u2013504\u2009929). No other predictors were identified. Within 12\u2009months after ceasing oral vancomycin in children who achieved remission, 52% relapsed. No clinical predictors, including vancomycin preparation, were established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Oral vancomycin solution was superior to capsules for inducing biomarker and colonoscopic remission in children with atypical colitis with\/without confirmed PSC. This finding warrants further investigation to ensure optimal use.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bcp.70121","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:48:09Z","timestamp":1749725289000},"source":"Crossref","is-referenced-by-count":3,"title":["Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4892-5710","authenticated-orcid":false,"given":"Laura","family":"R\u00e4is\u00e4nen","sequence":"first","affiliation":[{"name":"Tampere Center for Child, Adolescent, and Maternal Health Research, Faculty of Medicine and Health Technology Tampere University  Tampere Finland"},{"name":"Department of Paediatrics, Wellbeing Services County of Pirkanmaa Tampere University Hospital  Tampere Finland"},{"name":"Department of Gastroenterology, Hepatology, and Liver Transplant Queensland Children's Hospital  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariha","family":"Balouch","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Liver Transplant Queensland Children's Hospital  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Reilly","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Liver Transplant Queensland Children's Hospital  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Burgess","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Liver Transplant Queensland Children's Hospital  Brisbane Australia"},{"name":"Faculty of Medicine The University of Queensland  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lewindon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Liver Transplant Queensland Children's Hospital  Brisbane Australia"},{"name":"Queensland Children's Medical Research Institute; University of Queensland  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl16510"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894\u2010018\u20100620\u20102"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17936"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast\u20102024\u2010001605"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328\u2010020\u201001296\u20100"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000239"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3781"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102018\u2010317993"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.01.024"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201021.5.426"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:31:28Z","timestamp":1754904688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":10,"alternative-id":["10.1002\/bcp.70121"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70121","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"article-number":"bcp.70121"}}